Excellent point Doctor!

So true

Honored and grateful. Congratulations class of 2020.

#vote2020 No wait at NRG! Make time! Every vote counts

Statement by President-elect Biden:

#ESMO21 DESTINY-Breast03 👉 new standard of care for 2L HER2+ metastatic #breastcancer E che curve!!! 🙌🙌🙌 Breast Cancer Academy ESMO - Eur. Oncology

Congratulations to Ishwaria Subbiah for her new position as the Director of Faculty and Academic Wellness at MD Anderson. This is a tremendous responsibility and opportunity! So proud of her. Thank you for all you do. #HOWPG #breakingtheglassceiling #allstar — with Ishwaria Subbiah, MD MS FASCO

Multi factor analysis from our trial with durvalumab, trastuzumab and pertuzumab, presented by our breast division chair Polly Niravath Jenny C. Chang at #SABCS2024. Path CR 50% with a chemo free approach in HER2 enriched ER neg HER2 positive early breast cancer.

Shoutout to our overachieving fellow Inimfon Jackson for presenting her hard work at #SABCS24 - 3 Posters with 2 poster spotlights.  Mentors- Mariana Chavez Macgregor, Sharon Giordano, MD Anderson Cancer Center December 12 PS15-07 at 7-8:30am, P3-11-04 at 12:30-2pm PS16-09 at 5:30-7pm

PATINA study of induction THP > maintenance HP + ET +/- palbo in ER+HER2+ MBC. Takeaway: after 6 cycles induction THP, patients can expect nearly 4 years of maintenance HP/ET/palbo on avg before re-needing chemo/ADC!

In TAILORx (LN- HR+) pts w/ RS≥31 addition of anthracycline results in benefit in 5-yr DRFI (5% HR 0.32) vs TC 📏benefit most clear in tumor >2 cm ↗️Increasing RS≥31 corresponded to increasing benefit of addition of anthracycline #SABCS24 SABCS OncoAlert